CN1931232B - Oil-in-water nanometer perilla seed oil emulsion oral liquid and its preparation process - Google Patents
Oil-in-water nanometer perilla seed oil emulsion oral liquid and its preparation process Download PDFInfo
- Publication number
- CN1931232B CN1931232B CN200610104621XA CN200610104621A CN1931232B CN 1931232 B CN1931232 B CN 1931232B CN 200610104621X A CN200610104621X A CN 200610104621XA CN 200610104621 A CN200610104621 A CN 200610104621A CN 1931232 B CN1931232 B CN 1931232B
- Authority
- CN
- China
- Prior art keywords
- oil
- perilla seed
- surfactant
- seed oil
- oral liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000001335 perilla frutescens leaf extract Substances 0.000 title claims abstract description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 239000007788 liquid Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title description 13
- 239000000839 emulsion Substances 0.000 title description 2
- 239000007908 nanoemulsion Substances 0.000 claims abstract description 42
- 239000004094 surface-active agent Substances 0.000 claims abstract description 40
- 239000003921 oil Substances 0.000 claims abstract description 39
- 235000019198 oils Nutrition 0.000 claims abstract description 33
- 239000012153 distilled water Substances 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000004359 castor oil Substances 0.000 claims description 9
- 235000019438 castor oil Nutrition 0.000 claims description 9
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 9
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 4
- 229940057995 liquid paraffin Drugs 0.000 claims description 4
- 229940051841 polyoxyethylene ether Drugs 0.000 claims description 4
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 235000019489 Almond oil Nutrition 0.000 claims description 3
- 239000008168 almond oil Substances 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 239000010497 wheat germ oil Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 2
- 235000019439 ethyl acetate Nutrition 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 abstract description 33
- 239000003814 drug Substances 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 3
- 230000008859 change Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 238000004945 emulsification Methods 0.000 abstract description 2
- 239000012530 fluid Substances 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 230000001934 delay Effects 0.000 abstract 1
- 230000036267 drug metabolism Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000005303 weighing Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 12
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 12
- 235000004347 Perilla Nutrition 0.000 description 11
- 241000229722 Perilla <angiosperm> Species 0.000 description 11
- 238000012360 testing method Methods 0.000 description 8
- 238000010587 phase diagram Methods 0.000 description 7
- -1 RH-40) Polymers 0.000 description 6
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 229960004488 linolenic acid Drugs 0.000 description 6
- 239000004973 liquid crystal related substance Substances 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 235000019485 Safflower oil Nutrition 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 239000003813 safflower oil Substances 0.000 description 3
- 235000005713 safflower oil Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- HWGBHCRJGXAGEU-UHFFFAOYSA-N Methylthiouracil Chemical compound CC1=CC(=O)NC(=S)N1 HWGBHCRJGXAGEU-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000005338 heat storage Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036630 mental development Effects 0.000 description 1
- 229960002545 methylthiouracil Drugs 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000007785 strong electrolyte Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种水包油型紫苏子油纳米乳口服液,该纳米乳口服液是由表面活性剂、油、紫苏子油、蒸馏水按下述方法制备而成:按配方称取表面活性剂,单独使用或与助表面活性剂复配,计算HLB值,根据其HLB值,选择油,调其比例,使其乳化所需的HLB值与表面活性剂相的HLB相近;按规律改变表面活性剂相和油相的比例,向其中加入配方比例的紫苏子油,充分搅拌,在20℃~25℃缓慢加蒸馏水充分搅拌,直至形成澄清透明、粘度小且具有流动性的黄色或无色透明的O/W型纳米乳状液。本发明提高了紫苏子油在加工过程中的药物稳定性,提高生物利用度,延缓其在体内的药物代谢时间,减少辅料用量,降低生产成本,在医药领域有广阔的市场前景。The invention discloses an oil-in-water perilla seed oil nanoemulsion oral liquid. The nanoemulsion oral liquid is prepared from surfactant, oil, perilla seed oil and distilled water according to the following method: weighing according to the formula Surfactant, used alone or compounded with co-surfactant, calculate HLB value, select oil according to its HLB value, adjust its ratio, so that the HLB value required for emulsification is similar to the HLB of the surfactant phase; according to the law Change the ratio of the surfactant phase to the oil phase, add perilla seed oil in the formula ratio, stir well, slowly add distilled water at 20°C to 25°C and stir thoroughly until a clear, transparent, low viscosity and fluid yellow color is formed Or colorless and transparent O/W nanoemulsion. The invention improves the drug stability of the perilla seed oil in the processing process, improves the bioavailability, delays the drug metabolism time in the body, reduces the consumption of auxiliary materials, reduces the production cost, and has broad market prospects in the field of medicine.
Description
技术领域 technical field
本发明属于医药、食品和保健品领域,涉及一种医药配制品及其制备方法,具体地说是一种透明稳定的水包油型紫苏子油纳米乳口服液及其制备方法。 The invention belongs to the fields of medicine, food and health products, and relates to a medicine preparation and a preparation method thereof, in particular to a transparent and stable oil-in-water perilla seed oil nanoemulsion oral liquid and a preparation method thereof. the
背景技术 Background technique
紫苏始载于2500年前我国汉代最早的医药经典“神农本草经”。书中曰:“苏子味甘温,久服通神明轻身”,又曰:“苏者乃舒畅也,具有行气和血之功,故称苏”。其味辛性遇,具有降气消疾、平喘、润肠之功效。我国药典已收载,但其临床应用仅停留在将紫苏子用于水煎煮,降气消疾、平喘、润肠的水平上。迄今为止,无论临床或民间,均没有将紫苏进一步加以开发研究。 Perilla was first recorded in the earliest medical classic "Shen Nong's Herbal Classic" in the Han Dynasty in my country 2,500 years ago. The book says: "Su Zi tastes sweet and warm, long-term consumption can lighten the body", and it also says: "Su is comfortable and has the power of promoting qi and blood, so it is called Su." Its taste is pungent in nature, and it has the effects of lowering qi and eliminating illness, relieving asthma, and moistening the intestines. It has been recorded in Chinese Pharmacopoeia, but its clinical application only stays at the level of decocting perilla seed in water, lowering Qi and eliminating illness, relieving asthma and moistening intestines. So far, no matter clinical or folk, perilla has not been further developed and researched. the
现代医学研究发现紫苏子中不含胆固醇,而富含α-亚麻酸,含量可达51%~70%。α-亚麻酸是人体必需的脂肪酸,对人体具有多种生理调节功能,可降低血压、降低血脂、抗动脉硬化、预防心血管疾病、增强记忆力、预防老年痴呆症,促进智力发育,提高智商。1993年联合国粮农组织和世界卫生组织联合发表声明:鉴于α-亚麻酸的重要性和人类普遍缺乏的现状,决定在世界范围内专项推广α-亚麻酸。90年美、法、日等国立法在指定食品中必须添加α-亚麻酸,而我国人均摄入α-亚麻酸量不足世界卫生组织推荐量的一半。但是,紫苏子油溶解度差、物理性质不稳定,易挥发,易酸败,难以保存、其在水中分散的困难,利用率不高。 Modern medical research has found that perilla seeds do not contain cholesterol, but are rich in α-linolenic acid, with a content of 51% to 70%. α-linolenic acid is an essential fatty acid for the human body. It has a variety of physiological regulation functions on the human body. It can lower blood pressure, lower blood lipids, resist arteriosclerosis, prevent cardiovascular diseases, enhance memory, prevent Alzheimer's disease, promote mental development, and improve IQ. In 1993, the Food and Agriculture Organization of the United Nations and the World Health Organization jointly issued a statement: In view of the importance of α-linolenic acid and the general lack of human beings, it was decided to promote α-linolenic acid worldwide. In 1990, the laws of the United States, France, Japan and other countries must add α-linolenic acid to designated foods, while the per capita intake of α-linolenic acid in my country is less than half of the recommended amount by the World Health Organization. However, perilla seed oil has poor solubility, unstable physical properties, is volatile, easy to rancid, difficult to preserve, difficult to disperse in water, and low utilization rate. the
发明内容 Contents of the invention
针对上述现有技术的问题和缺陷,本发明的目的在于提供一种含量均匀准 确、质量稳定,且制备简便的紫苏子油纳米乳口服液。 For the problems and defects of the above-mentioned prior art, the object of the present invention is to provide a kind of even and accurate content, stable quality, and easy to prepare perilla seed oil nanoemulsion oral liquid. the
实现上述发明目的的技术方案是水包油型紫苏子油纳米乳口服液,它是由下述重量配比的原料组成: The technical scheme that realizes the above-mentioned invention object is oil-in-water type perilla seed oil nanoemulsion oral liquid, and it is made up of the raw material of following weight ratio:
表面活性剂 21.19%~45.00% Surfactant 21.19%~45.00%
油 4.03%~10.00% Oil 4.03%~10.00%
紫苏子油 0.10%~15.00% Perilla seed oil 0.10%~15.00%
蒸馏水 50%~72.00% Distilled water 50%~72.00%
在表面活性剂的选择上,本发明选用无毒性和生物相容性好的非离子型表面活性剂。非离子型表面活性剂在溶液中比较稳定,不易受强电解质、无机盐类的影响,也不易受酸碱的影响,并且与其他表面活性剂的相容性好,溶血作用较小。理论上,O/W型纳米乳状液的制备需要表面活性剂的HLB值介于8~18之间,考虑到制备工艺的简单性,即纳米乳的易形成性和制备出来的纳米乳的稳定性,本发明选用HLB介于10~15之间的液态非离子型表面活性剂,或者与一种HLB<10的非离子表面活性剂复配。可选用的表面活性剂有:蓖麻油聚氧乙烯醚(如EL-40)、氢化蓖麻油聚氧乙烯醚(如RH-40)、吐温-80和司盘-80中的一种或几种混合物。 In the selection of surfactants, the present invention selects non-ionic surfactants with good non-toxicity and biocompatibility. Non-ionic surfactants are relatively stable in solution, not easily affected by strong electrolytes, inorganic salts, and acid-base, and have good compatibility with other surfactants, and have less hemolysis. Theoretically, the preparation of O/W nanoemulsion requires the HLB value of the surfactant to be between 8 and 18. Considering the simplicity of the preparation process, that is, the ease of forming the nanoemulsion and the stability of the prepared nanoemulsion In the present invention, a liquid nonionic surfactant with HLB between 10 and 15 is selected, or compounded with a nonionic surfactant with HLB<10. The optional surfactants are: one or more of castor oil polyoxyethylene ether (such as EL-40), hydrogenated castor oil polyoxyethylene ether (such as RH-40), Tween-80 and Span-80 kind of mixture. the
本发明根据当乳化油相所需的表面活性剂的HLB与表面活性剂相近时,所形成的乳状液稳定的原则,选用的油脂有液体石蜡、维生素E油、小麦胚芽油、杏仁油、乙酸乙酯和橄榄油的一种或几种混合物。这些油常温下呈液态、无不良气味。 The present invention is based on the principle that when the HLB of the surfactant required for the emulsified oil phase is similar to the surfactant, the formed emulsion is stable. The oils selected include liquid paraffin, vitamin E oil, wheat germ oil, almond oil, and acetic acid One or more mixtures of ethyl esters and olive oil. These oils are liquid at room temperature and have no bad smell. the
本发明的另一目的是提供水包油型紫苏子油纳米乳口服液的制备方法,步聚如下: Another object of the present invention is to provide the preparation method of oil-in-water perilla seed oil nanoemulsion oral liquid, the steps are as follows:
(1)表面活性剂相的配制 按配方比例称取表面活性剂,单独使用或与助表面活性按比例复配,计算该体系的HLB值,充分搅拌均匀。常见乳化剂的HLB值可以在一些化工手册中查到,如化工出版社的《化学产品手册》。由于表面活性剂的亲水亲油平衡(HLB)值具有加合性,可用质量平均法求出表面活性剂的HLB值。例如,两种表面活性剂A、B混合后,其混合表面活性剂的亲水亲油平衡HLBAB值为 (1) Preparation of surfactant phase Weigh the surfactant according to the proportion of the formula, use it alone or compound it with co-surfactant in proportion, calculate the HLB value of the system, and stir well. The HLB values of common emulsifiers can be found in some chemical handbooks, such as "Chemical Product Handbook" published by Chemical Press. Since the hydrophilic-lipophilic balance (HLB) value of the surfactant is additive, the HLB value of the surfactant can be obtained by the mass average method. For example, after two surfactants A and B are mixed, the hydrophilic-lipophilic equilibrium HLBAB value of the mixed surfactant is
HLBAB=(WAHLBA+WBHLBB)/(WA+WB) HLBAB=(WAHLBA+WBHLBB)/(WA+WB)
式中WA,WB——混合物表面活性剂A、B的质量; In the formula, WA, WB——the quality of mixture surfactant A, B;
HLBA,HLBB——表面活性剂A、B的HLB值。 HLBA, HLBB - HLB values of surfactants A and B. the
(2)油相的配制 根据表面活性剂相的HLB值,选择一种或几种油,调其比例,使其乳化所需的HLB值与表面活性剂相的HLB相近。 (2) Preparation of the oil phase According to the HLB value of the surfactant phase, select one or several oils and adjust their ratio so that the HLB value required for emulsification is similar to the HLB of the surfactant phase. the
(3)按9∶1~1∶9的规律改变表面活性剂相和油相的比例,向其中加入配方比例的紫苏子油,充分搅拌,在20℃~25℃缓慢加蒸馏水充分搅拌,直至形成澄清透明、粘度小且具有流动性的黄色或无色的O/W型纳米乳状液。 (3) Change the ratio of the surfactant phase and the oil phase according to the rule of 9:1 to 1:9, add perilla seed oil in the formula ratio therein, stir fully, slowly add distilled water at 20°C to 25°C and stir fully, Until a clear, transparent, low viscosity and fluid yellow or colorless O/W nanoemulsion is formed. the
本发明经透射电子显微镜检测,液滴直径分布在10~100nm之间,外观为黄色或无色透明液体,具有很好的稳定性: The invention is detected by a transmission electron microscope, the droplet diameter is distributed between 10-100nm, the appearance is yellow or colorless transparent liquid, and has good stability:
1、经时稳定性 1. Stability over time
经时稳定性是指纳米乳口服液在室温自然变化条件下贮藏时,外观随时间延长而发生变化的程度。该紫苏子油纳米乳口服液持久透明,未发现浑浊或沉淀,则说明经时稳定性好。这是评价纳米乳口服液的一个重要指标。 Stability over time refers to the extent to which the appearance of the nanoemulsion oral liquid changes over time when it is stored under natural room temperature conditions. The perilla seed oil nanoemulsion oral liquid is persistently transparent, and no turbidity or precipitation is found, which shows that it has good stability over time. This is an important indicator for evaluating nanoemulsion oral liquid. the
2、热贮稳定性 2. Heat storage stability
将该紫苏子油纳米乳口服液置于试管,密封,置于37℃恒温水浴箱中贮存14天,该液热贮后外观透明。 The perilla seed oil nanoemulsion oral liquid was placed in a test tube, sealed, and stored in a constant temperature water bath at 37°C for 14 days. The liquid appeared transparent after thermal storage. the
3、抗冷冻稳定性 3. Freezing stability
将该紫苏子油纳米乳口服液在冰箱中-4℃保存一周后。恢复至室温。如果纳米乳口服液在-4℃成固体,恢复至室温,恢复至透明,且放置一周后继续透明,则认为抗冷冻性好。 The perilla seed oil nanoemulsion oral liquid was stored in the refrigerator at -4°C for one week. Return to room temperature. If the nanoemulsion oral solution becomes solid at -4°C, returns to room temperature, returns to transparent, and remains transparent after one week, it is considered that the freezing resistance is good. the
4、加速稳定性 4. Acceleration stability
将该紫苏子油纳米乳口服液置于试管,密封,在15000r/min的转速下离心20分钟,没有分层,仍澄清透明。 The perilla seed oil nanoemulsion oral solution was placed in a test tube, sealed, and centrifuged at a speed of 15,000 r/min for 20 minutes. There was no stratification, and it was still clear and transparent. the
本发明的水包油型紫苏子油纳米乳口服液具有降低血压、降低血脂、抗动脉硬化、预防心血管疾病、增强记忆力、预防老年痴呆症,促进智力发育,提高智商等多方面的作用。临床上可用于高血脂症、高血压症、动脉粥样硬化、老年性痴呆症、支气管哮喘等疾病的治疗。用法:口服,每天0.3g。 The oil-in-water type perilla seed oil nanoemulsion oral liquid of the present invention has various effects such as lowering blood pressure, lowering blood fat, resisting arteriosclerosis, preventing cardiovascular disease, enhancing memory, preventing senile dementia, promoting intellectual development, and improving IQ. . Clinically, it can be used for the treatment of hyperlipidemia, hypertension, atherosclerosis, senile dementia, bronchial asthma and other diseases. Usage: Oral, 0.3g per day. the
本发明的水包油型紫苏子油纳米乳口服液与现有技术相比,具有以下优点: Compared with the prior art, the oil-in-water perilla oil nanoemulsion oral liquid has the following advantages:
1)热力学稳定性高。制备时操作比较简单,不分相、不沉淀,贮存稳定性提高; 1) High thermodynamic stability. The operation is relatively simple during preparation, no phase separation, no precipitation, and the storage stability is improved;
2)透光性好,任何不均匀性或沉淀物的存在易被发现,感观品质提高; 2) Good light transmission, any inhomogeneity or the existence of sediment can be easily found, and the sensory quality is improved;
3)防腐性能提高,因为分散相液体比较小,能防止细菌的侵入,同时增加一些有效成份的溶解度; 3) The anti-corrosion performance is improved, because the dispersed phase liquid is relatively small, which can prevent the invasion of bacteria and increase the solubility of some active ingredients;
4)具有良好的增溶作用,可以有效的提高难溶性药物的溶解度; 4) It has a good solubilization effect, which can effectively improve the solubility of insoluble drugs;
5)能提高紫苏子油的溶解性,延缓紫苏子油的消退时间,从而提高了紫苏子油的生物利用度; 5) It can improve the solubility of perilla seed oil and delay the disappearance time of perilla seed oil, thereby improving the bioavailability of perilla seed oil;
6)方法工艺简单,适合规模化生产。 6) The method has simple process and is suitable for large-scale production. the
具体实施方式 Detailed ways
以下通过药效学试验和对比试验来进一步阐述本发明所述药物的有益效果。 The beneficial effect of the medicine of the present invention will be further elaborated below through pharmacodynamic tests and comparative tests. the
试验例1紫苏子油纳米乳口服液降血脂药效与其他制剂的对比试验 Test Example 1 Comparative test of perilla seed oil nanoemulsion oral liquid for lowering blood fat and other preparations
选取年龄、体重基本相同的Wistar大鼠9只,用3%胆固醇,10%猪油,0.2%甲基硫氧嘧啶,86.8%基础饲料制成的高脂饲料喂养20d建立高脂模型。平均分为3组,第一组用汕头市保瑞药业有限公司生产的批号为_TY3483的千林紫苏油软胶囊(每粒含8mg紫苏油)治疗,大鼠每只每天服用2次,每次1粒,用开口器辅助,将胶囊给大鼠灌服。第二组用沈阳东宇馨波尔科技有限公司生产的卫食健字(2000)第0698号东宇血平康治疗,大鼠每只每天1次服用3粒,研碎和在料中饲喂。第三组用本发明的紫苏子油纳米乳口服液治疗,大鼠每只每天口服0.3g(含紫苏子油15mg),3周后,测各组大鼠的血清甘油三醋(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、LDL-C与高密度脂蛋白胆固醇(HDL-C)的比值(LDL-C/HDL-C)和致动脉粥样硬化指数(Al)的增加值。结果发现三组大鼠的以上各项指标均不同程度的降低,尤其以第三组的最为明显。说明紫苏子油纳米乳口服液在降血脂方面功效强于千林紫苏油软胶囊和东宇血平康,而且剂量低。 Select 9 Wistar rats with basically the same age and body weight, and feed them with a high-fat diet made of 3% cholesterol, 10% lard, 0.2% methylthiouracil, and 86.8% basal feed for 20 days to establish a high-fat model. Divided into 3 groups on average, the first group was treated with Qianlin Perilla Oil Soft Capsules (each containing 8 mg perilla oil) produced by Shantou Baorui Pharmaceutical Co., Ltd. with the batch number _TY3483, and each rat took 2 times a day , 1 capsule each time, with the aid of a gag, the capsules were fed to rats. The second group was treated with Dongyu Xuepingkang produced by Shenyang Dongyu Xinboer Technology Co., Ltd. (2000) No. 0698. Each rat took 3 capsules once a day, crushed and fed in the feed. Hello. The third group is treated with perilla seed oil nanoemulsion oral liquid of the present invention, and each rat is oral 0.3g (containing perilla seed oil 15mg) every day, and after 3 weeks, the serum triglyceride (TG) of each group of rats is measured. ), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), ratio of LDL-C to high-density lipoprotein cholesterol (HDL-C) (LDL-C/HDL-C), and atherosclerotic Increased value of the index (Al). As a result, it was found that the above indicators of the three groups of rats were all reduced to varying degrees, especially the third group was the most obvious. It shows that perilla seed oil nanoemulsion oral liquid is more effective in lowering blood lipid than Qianlin perilla oil soft capsule and Dongyu Xuepingkang, and the dose is lower. the
试验例2紫苏子油纳米乳口服降血脂药效与其他制剂的对比试验 Test Example 2 Comparative test of perilla seed oil nanoemulsion oral hypolipidemic efficacy and other preparations
选原发性高血压的幼鼠(SHR-SP)12只,雌雄各半,按数量、性别平均分为三组,第一组用紫苏子油纳米乳口服液10%(含紫苏子油15mg)拌料饲喂,第二组用上海地源食品有限公司生产的红花油6%(含红花油15mg)拌料饲喂, 第三组用汕头市保瑞药业有限公司生产的批号为_TY3483的千林紫苏油软胶囊(每粒含8mg紫苏油),每只每天服用2次,每次1粒,结果第一组的雄性鼠比第二、第三组的雄性鼠的平均生存时间延长17%、15%,雌性鼠的平均生存时间比雄性鼠延长40%、32%;第一组组舒张压比第二和第三组平均低10%(2.8kPa);死鼠的脑部检查结果表明,引起死亡的主要原因是脑溢血。充分说明紫苏子油纳米乳口服液的药效高于红花油和千林紫苏油软胶囊。 Choose 12 young rats with essential hypertension (SHR-SP), half male and half male, and divide them into three groups on average according to quantity and sex. The first group is given perilla seed oil nanoemulsion oral liquid 10% oil 15mg) mixed material feeding, the second group was fed with 6% safflower oil (containing safflower oil 15mg) mixed material produced by Shanghai Diyuan Food Co., Ltd., and the third group was fed with Shantou Baorui Pharmaceutical Co., Ltd. The batch number is _TY3483 Qianlin perilla oil soft capsules (each containing 8mg perilla oil), each take 2 times a day, 1 capsule each time, the result is that the male rats in the first group are more than the male rats in the second and third groups. The average survival time of the rats was prolonged by 17%, 15%, and the average survival time of the female rats was 40%, 32% longer than that of the male rats; the diastolic pressure of the first group was 10% lower (2.8kPa) on average than the second and third groups; The brain examination results of the dead mice showed that the main cause of death was cerebral hemorrhage. It fully shows that the efficacy of perilla seed oil nanoemulsion oral liquid is higher than that of safflower oil and Qianlin perilla oil soft capsule. the
以下通过发明人给出的实施例来进一步阐述本发明紫苏子油纳米乳口服液的制备方法。 The preparation method of perilla seed oil nanoemulsion oral liquid of the present invention is further described by the examples given by the inventor below. the
实施例1 Example 1
用通过计算HLB值所选定的油和表面活性剂、助表面活性剂按照9∶1~1∶9的规律绘制伪三元相图确定最佳比例。精确称取吐温-80 1.8g,司盘-800.6g,液体石蜡0.6g,放入烧杯,在25℃室温条件下,手动搅拌将其充分混合均匀,将0.1g紫苏子油直接加入,搅拌充分,然后向其中缓慢加入蒸馏水,边加蒸馏水边手动搅拌,开始时体系黏度较小,随着蒸馏水量的增加,体系会变黏稠,此时体系可能会出现液晶态或油包水型纳米乳,继续滴加并不断搅拌,当体系突然变稀时,此时产生的即是稳定的黄色透明水包油型紫苏子油纳米乳口服液,称其总重量为10.0g。 Use the oil selected by calculating the HLB value, surfactant, and co-surfactant to draw a pseudo-ternary phase diagram according to the rule of 9:1 to 1:9 to determine the optimal ratio. Accurately weigh 1.8g of Tween-80, 0.6g of Span-80, and 0.6g of liquid paraffin, put them into a beaker, and mix them thoroughly by manual stirring at room temperature of 25°C, then add 0.1g of perilla seed oil directly, Stir well, then slowly add distilled water to it, and manually stir while adding distilled water. At the beginning, the system viscosity is small. As the amount of distilled water increases, the system will become viscous. At this time, the system may appear liquid crystal or water-in-oil nanometer. Milk, continue to add dropwise and constantly stir, when the system suddenly becomes thinner, what produce now is the stable yellow transparent oil-in-water type perilla seed oil nanoemulsion oral liquid, claiming that its total weight is 10.0g. the
实施例2 Example 2
用通过计算HLB值所选定的油和表面活性剂、助表面活性剂按照9∶1~1∶9的规律绘制伪三元相图确定最佳比例。精确称取聚氧乙烯氢化蓖麻油3.6g,小麦胚芽油0.4g,维生素E油0.05g,放入烧杯,在24℃室温条件下,手动搅拌将其充分混合均匀,将0.5g紫苏子油直接加入,搅拌直至全部溶解,然后向其中缓慢加入蒸馏水,边加蒸馏水边手动搅拌,开始时体系黏度较小,随着蒸馏 水量的增加,体系会变黏稠,此时体系可能会出现液晶态或油包水型纳米乳,继续滴加并不断搅拌,当体系突然变稀时,此时产生的即是稳定的无色透明水包油型紫苏子油纳米乳口服液,称其总重量为10.35g。 Use the oil selected by calculating the HLB value, surfactant, and co-surfactant to draw a pseudo-ternary phase diagram according to the rule of 9:1 to 1:9 to determine the optimal ratio. Accurately weigh 3.6g of polyoxyethylene hydrogenated castor oil, 0.4g of wheat germ oil, and 0.05g of vitamin E oil, put them into a beaker, and mix them thoroughly by manual stirring at room temperature of 24°C. Add it directly, stir until it is completely dissolved, then slowly add distilled water to it, and manually stir while adding distilled water. Water-in-oil type nanoemulsion, continue to drop and constantly stir, when the system suddenly becomes thinner, what produce this moment is the stable colorless transparent oil-in-water type perilla seed oil nanoemulsion oral liquid, and its total weight is called 10.35g. the
实施例3 Example 3
用通过计算HLB值所选定的油和表面活性剂、助表面活性剂按照9∶1~1∶9的规律绘制伪三元相图确定最佳比例。精确称取聚氧乙烯氢化蓖麻油4.5g,橄榄油0.5g,放入烧杯,在25℃室温条件下,手动搅拌将其充分混合均匀,将1.0g紫苏子油直接加入,搅拌直至全部溶解,然后向其中缓慢加入蒸馏水,边加蒸馏水边手动搅拌,开始时体系黏度较小,随着蒸馏水量的增加,体系会变黏稠,此时体系可能会出现液晶态或油包水型纳米乳,继续滴加并不断搅拌,当体系突然变稀时,此时产生的即是稳定的无色透明水包油型紫苏子油纳米乳口服液,称其总重量为10.0g。 Use the oil selected by calculating the HLB value, surfactant, and co-surfactant to draw a pseudo-ternary phase diagram according to the rule of 9:1 to 1:9 to determine the optimal ratio. Accurately weigh 4.5g of polyoxyethylene hydrogenated castor oil and 0.5g of olive oil, put them into a beaker, and mix them thoroughly by manual stirring at room temperature of 25°C, add 1.0g of perilla seed oil directly, and stir until completely dissolved , then slowly add distilled water to it, and stir manually while adding distilled water. At the beginning, the system viscosity is small. As the amount of distilled water increases, the system will become viscous. At this time, the system may appear liquid crystal or water-in-oil nanoemulsion. Continue to add dropwise and constantly stir, when the system becomes thinner suddenly, what produces now is the stable colorless transparent oil-in-water type perilla seed oil nanoemulsion oral liquid, claiming that its total weight is 10.0g. the
实施例4 Example 4
用通过计算HLB值所选定的油和表面活性剂、助表面活性剂按照9∶1~1∶9的规律绘制伪三元相图确定最佳比例。精确称取聚氧乙烯氢化蓖麻油4.0g,杏仁油1.0g,放入烧杯,在20℃室温条件下,手动搅拌将其充分混合均匀,将1.5g紫苏子油直接加入,搅拌直至全部溶解,然后向其中缓慢加入蒸馏水,边加蒸馏水边手动搅拌,开始时体系黏度较小,随着蒸馏水量的增加,体系会变黏稠,此时体系可能会出现液晶态或油包水型纳米乳,继续滴加并不断搅拌,当体系突然变稀时,此时产生的即是稳定的无色透明水包油型紫苏子油纳米乳口服液,称其总重量为10.0g。 Use the oil selected by calculating the HLB value, surfactant, and co-surfactant to draw a pseudo-ternary phase diagram according to the rule of 9:1 to 1:9 to determine the optimal ratio. Accurately weigh 4.0g of polyoxyethylene hydrogenated castor oil and 1.0g of almond oil, put them into a beaker, and mix them thoroughly by manual stirring at room temperature of 20°C, add 1.5g of perilla oil directly, and stir until completely dissolved , then slowly add distilled water to it, and stir manually while adding distilled water. At the beginning, the system viscosity is small. As the amount of distilled water increases, the system will become viscous. At this time, the system may appear liquid crystal or water-in-oil nanoemulsion. Continue to add dropwise and constantly stir, when the system becomes thinner suddenly, what produces now is the stable colorless transparent oil-in-water type perilla seed oil nanoemulsion oral liquid, claiming that its total weight is 10.0g. the
实施例5 Example 5
用通过计算HLB值所选定的油和表面活性剂、助表面活性剂按照9∶1~1∶9的规律绘制伪三元相图确定最佳比例。精确称取吐温-80 1.40g,司盘-800.70g,液体石蜡0.90g,放入烧杯,在22℃室温条件下,手动搅拌将其充分混合均匀,将0.01g紫苏子油直接加入,搅拌充分,然后向其中缓慢加入蒸馏水,边加蒸馏水边手动搅拌,开始时体系黏度较小,随着蒸馏水量的增加,体系会变黏稠,此时体系可能会出现液晶态或油包水型纳米乳,继续滴加并不断搅拌,当体系突然变稀时,此时产生的即是稳定的黄色透明水包油型紫苏子油纳米乳口服液,称其总重量为9.91g。 Use the oil selected by calculating the HLB value, surfactant, and co-surfactant to draw a pseudo-ternary phase diagram according to the rule of 9:1 to 1:9 to determine the optimal ratio. Accurately weigh 1.40g of Tween-80, 0.70g of Span-80, and 0.90g of liquid paraffin, put them into a beaker, and mix them thoroughly by manual stirring at room temperature of 22°C, add 0.01g of perilla seed oil directly, Stir well, then slowly add distilled water to it, and manually stir while adding distilled water. At the beginning, the system viscosity is small. As the amount of distilled water increases, the system will become viscous. At this time, the system may appear liquid crystal or water-in-oil nanometer. Milk, continue to drop and constantly stir, when the system suddenly becomes thinner, what produce now is the stable yellow transparent oil-in-water type perilla seed oil nanoemulsion oral liquid, claiming that its total weight is 9.91g. the
实施例6 Example 6
用通过计算HLB值所选定的油和表面活性剂、助表面活性剂按照9∶1~1∶9的规律绘制伪三元相图确定最佳比例。精确称取聚氧乙烯蓖麻油4.5g,乙酸乙酯0.5g,维生素E油0.03g,放入烧杯,在24℃室温条件下,手动搅拌将其充分混合均匀,将0.07g紫苏子油直接加入,搅拌充分,然后向其中缓慢加入蒸馏水,边加蒸馏水边手动搅拌,开始时体系黏度较小,随着蒸馏水量的增加,体系会变黏稠,此时体系可能会出现液晶态或油包水型纳米乳,继续滴加并不断搅拌,当体系突然变稀时,此时产生的即是稳定的无色透明水包油型紫苏子油纳米乳口服液,称其重量为11.1g。 Use the oil selected by calculating the HLB value, surfactant, and co-surfactant to draw a pseudo-ternary phase diagram according to the rule of 9:1 to 1:9 to determine the optimal ratio. Accurately weigh 4.5g of polyoxyethylene castor oil, 0.5g of ethyl acetate, and 0.03g of vitamin E oil, put them into a beaker, and mix them thoroughly by manual stirring at room temperature of 24°C, and directly add 0.07g of perilla seed oil Add, stir thoroughly, then slowly add distilled water to it, and manually stir while adding distilled water. At the beginning, the system viscosity is small. As the amount of distilled water increases, the system will become viscous. At this time, the system may appear liquid crystal or water-in-oil Type nanoemulsion, continue to drop and constantly stir, when system suddenly becomes thinner, what produce this moment is stable colorless transparent oil-in-water type perilla seed oil nanoemulsion oral liquid, claims its weight as 11.1g. the
实施例7 Example 7
用通过计算HLB值所选定的油和表面活性剂、助表面活性剂按照9∶1~1∶9的规律绘制伪三元相图确定最佳比例。精确称取聚氧乙烯氢化蓖麻油3.6g,乙酸乙酯0.4g,维生素E油0.02g,放入烧杯,在23℃室温条件下,手动搅拌将其充分混合均匀,将0.8g紫苏子油直接加入,搅拌充分,然后向其中缓慢加 入蒸馏水,边加蒸馏水边手动搅拌,开始时体系黏度较小,随着蒸馏水量的增加,体系会变黏稠,此时体系可能会出现液晶态或油包水型纳米乳,继续滴加并不断搅拌,当体系突然变稀时,此时产生的即是稳定的无色透明水包油型紫苏子油纳米乳口服液,称其重量为10.42g。 Use the oil selected by calculating the HLB value, surfactant, and co-surfactant to draw a pseudo-ternary phase diagram according to the rule of 9:1 to 1:9 to determine the optimal ratio. Accurately weigh 3.6g of polyoxyethylene hydrogenated castor oil, 0.4g of ethyl acetate, and 0.02g of vitamin E oil, put them into a beaker, and mix them thoroughly by manual stirring at room temperature of 23°C, and mix 0.8g of perilla seed oil Add directly, stir thoroughly, then slowly add distilled water, and manually stir while adding distilled water. At the beginning, the viscosity of the system is small. As the amount of distilled water increases, the system will become viscous. At this time, the system may appear liquid crystal or oily. Water-in-water nanoemulsion, continue to drop and stir continuously, when the system suddenly becomes thinner, what is produced at this time is a stable colorless and transparent oil-in-water perilla seed oil nanoemulsion oral liquid, which weighs 10.42g . the
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610104621XA CN1931232B (en) | 2006-09-21 | 2006-09-21 | Oil-in-water nanometer perilla seed oil emulsion oral liquid and its preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610104621XA CN1931232B (en) | 2006-09-21 | 2006-09-21 | Oil-in-water nanometer perilla seed oil emulsion oral liquid and its preparation process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1931232A CN1931232A (en) | 2007-03-21 |
| CN1931232B true CN1931232B (en) | 2011-11-09 |
Family
ID=37877354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610104621XA Expired - Fee Related CN1931232B (en) | 2006-09-21 | 2006-09-21 | Oil-in-water nanometer perilla seed oil emulsion oral liquid and its preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1931232B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101032507B (en) * | 2007-04-06 | 2010-09-29 | 西北农林科技大学 | A kind of erythromycin nanoemulsion antibacterial drug and preparation method thereof |
| CN101933975A (en) * | 2010-09-08 | 2011-01-05 | 西北大学 | Preparation method of nanoemulsion of high-efficiency active part of magnolia volatile oil |
| CN102166270A (en) * | 2011-04-06 | 2011-08-31 | 西北农林科技大学 | Oil-in-water type dried orange peel oil nano-emulsion and preparation method thereof |
| CN102166175B (en) * | 2011-04-06 | 2012-06-06 | 咸阳职业技术学院 | Anti-aging folia perillae acutae oil nano-emulsion cosmetic |
| CN102166233A (en) * | 2011-04-06 | 2011-08-31 | 西北农林科技大学 | Oil-in-water type sea buckthorn oil nano-emulsion oral liquid and preparation method thereof |
| CN102416056A (en) * | 2011-11-19 | 2012-04-18 | 西北农林科技大学 | Compound nanoemulsion oral liquid for reducing blood fat and preparation method thereof |
| CN102397405A (en) * | 2011-11-28 | 2012-04-04 | 西北农林科技大学 | A kind of compound bergamot oil nanoemulsion composition and preparation method thereof |
| CN102579580A (en) * | 2012-03-08 | 2012-07-18 | 西北农林科技大学 | Oil-in-water type compound ylang ylang oil nano-emulsion oral solution and preparation method thereof |
| CN103990105B (en) * | 2014-05-28 | 2016-01-20 | 北华大学 | For composition and method of making the same and the application of memory reinforcing |
| CN104305119A (en) * | 2014-09-26 | 2015-01-28 | 杭州杭曼香精有限公司 | Microemulsified essence and preparing method thereof |
| CN109744325A (en) * | 2019-03-06 | 2019-05-14 | 吉林大学 | A kind of nanoemulsion system and preparation method based on perilla oil or linseed oil |
| CN117837634A (en) * | 2023-12-14 | 2024-04-09 | 江苏省农业科学院 | Preparation method and application of nanoemulsion embedded with perilla leaf oil and lysozyme |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1178084A (en) * | 1996-09-28 | 1998-04-08 | 毛文岳 | Production of health care food additives enhanced by perilla containing alpha-linolenic acid richly |
| CN1184634A (en) * | 1996-12-13 | 1998-06-17 | 上海卓越医药科技有限公司 | Omega -3 capsule and method for preparing same |
-
2006
- 2006-09-21 CN CN200610104621XA patent/CN1931232B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1178084A (en) * | 1996-09-28 | 1998-04-08 | 毛文岳 | Production of health care food additives enhanced by perilla containing alpha-linolenic acid richly |
| CN1184634A (en) * | 1996-12-13 | 1998-06-17 | 上海卓越医药科技有限公司 | Omega -3 capsule and method for preparing same |
Non-Patent Citations (4)
| Title |
|---|
| 嵇志红等.植物提取剂紫苏油对大鼠血压及心率的影响.中国临床康复第8卷 第3期.2004,第8卷(第3期),464-465. |
| 嵇志红等.植物提取剂紫苏油对大鼠血压及心率的影响.中国临床康复第8卷 第3期.2004,第8卷(第3期),464-465. * |
| 徐章华等.苏子油对大鼠血脂及血液流变性的影响.营养学报第19卷 第1期.1997,第19卷(第1期),11-15. |
| 徐章华等.苏子油对大鼠血脂及血液流变性的影响.营养学报第19卷 第1期.1997,第19卷(第1期),11-15. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1931232A (en) | 2007-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1931232B (en) | Oil-in-water nanometer perilla seed oil emulsion oral liquid and its preparation process | |
| CN104187627B (en) | A kind of blood-fat reducing composition and the application had in the health food of hypolipemic function in preparation thereof | |
| CN114158733B (en) | Oil gel and preparation method and use thereof | |
| JP2021526511A (en) | Parenteral nutrition | |
| TW201028106A (en) | Liquid diet | |
| US20200128864A1 (en) | Edible, shelf-stable, water-soluble oil-in-syrup emulsions of microparticle-encapsulated cannabinoids and uses thereof | |
| CN104522649A (en) | Perilla seed oil and DHA (docosahexenoic acid) algal oil containing soft capsule and preparation method thereof | |
| CN102166233A (en) | Oil-in-water type sea buckthorn oil nano-emulsion oral liquid and preparation method thereof | |
| TW200803879A (en) | Composition for improvement of lipid metabolism | |
| CN102416056A (en) | Compound nanoemulsion oral liquid for reducing blood fat and preparation method thereof | |
| TWI743769B (en) | Liposome composition with adipocyte specificity and preparation process thereof | |
| JPWO2005074960A1 (en) | Functional beverages and compositions | |
| JPH04290822A (en) | Allergy preventing medicine and food | |
| CN101816423A (en) | Purple perilla seed oil lipid emulsion oral solution, beverage and manufacturing method thereof | |
| CN104288344A (en) | Applications of a Pu'er tea extract product in preparation of medicines or foods adjusting intestinal flora and relaxing the bowels | |
| CN109744325A (en) | A kind of nanoemulsion system and preparation method based on perilla oil or linseed oil | |
| CN105726478A (en) | Oral EPA(Eicoeapentaenoic acid) O/W type nanoemulsion and preparation method thereof | |
| JP5707026B2 (en) | Long-term weight maintenance | |
| CN100528148C (en) | Oil-in-water type nanometer peonol emulsion oral liquid and its preparation process | |
| JP2018104372A (en) | Composition containing krill oil and fish oil and perilla oil | |
| CN103704849B (en) | Energy bar antioxidant and preparation method thereof and the energy bar containing this antioxidant | |
| EP2744355B1 (en) | Edible composition comprising sterol | |
| CN102579580A (en) | Oil-in-water type compound ylang ylang oil nano-emulsion oral solution and preparation method thereof | |
| JP2006306813A (en) | Mast cell increase inhibitor | |
| CN100528171C (en) | Oil-in-water baicalin nano-milk oral liquid and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111109 Termination date: 20120921 |